Pharmacogenomics in Psychiatric Practice

Clinics in Laboratory Medicine

Volumn 36, Issue 3, 2016, Pages 507-523

  El Mallakh, Rif S ^a   Roberts, R Jeannie ^a   El Mallakh, Peggy L ^b   Findlay, Lillian Jan ^b   Reynolds, Kristen K ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF NURSING   (United States)

Author keywords

2D6; Antidepressants; Antipsychotics; CYP2D6; OPRM1; Pharmacogenomic testing; Psychiatric pharmacogenomics; SLC6A4

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACAMPROSATE; AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUPRENORPHINE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; DISULFIRAM; DOPAMINE 2 RECEPTOR; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POTASSIUM CHANNEL; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALCOHOLISM; COCAINE DEPENDENCE; COGNITIVE DEFECT; DEPRESSION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; METABOLIC DISORDER; METHAMPHETAMINE DEPENDENCE; MOOD DISORDER; NONHUMAN; OPIATE ADDICTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; ADVERSE DRUG REACTION; GENETICS; MENTAL DISEASE; PHARMACOGENETICS; PSYCHIATRY;

DEPRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC TESTING; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY;

EID: 84989934350     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2016.05.001     Document Type: Review

References (115)

1. 1 Winner, J.G., Carhart, J.M., Altar, C.A., et al. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 16 (2013), 219–227.
2. 2 Altar, C.A., Carhart, J.M., Allen, J.D., et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 15:5 (2015), 443–451.
3. 3 Sjöqvist, F., Bertilsson, L., Clinical pharmacology of antidepressant drugs: pharmacogenetics. Adv Biochem Psychopharmacol 39 (1984), 359–372.
4. 4 Kane, J.M., Lieberman, J., The efficacy of amoxapine, maprotiline, and trazodone in comparison to imipramine and amitriptyline: a review of the literature. Psychopharmacol Bull 20:2 (1984), 240–249.
5. 5 Burgess, C.D., Turner, P., Cardiotoxicity of antidepressant drugs. Neuropharmacology 19:12 (1980), 1195–1199.
6. 6 Starkey, I.R., Lawson, A.A., Poisoning with tricyclic and related antidepressants–a ten-year review. Q J Med 49:193 (1980), 33–49.
7. 7 Preskorn, S.H., Irwin, H.A., Toxicity of tricyclic antidepressants–kinetics, mechanism, intervention: a review. J Clin Psychiatry 43:4 (1982), 151–156.
8. 8 Chen, S., Chou, W.H., Blouin, R.A., et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:5 (1996), 522–534.
9. 9 Marshall, Z.T., Lippmann, S.B., Tricyclic antidepressant blood levels. Am Fam Physician 37:3 (1988), 251–254.
10. 10 Schosser, A., Serretti, A., Souery, D., et al. European Group for the Study of Resistant Depression (GSRD)–where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 22:7 (2012), 453–468.
11. 11 Duan, L., Mukherjee, E.M., Narayan, D., Tailoring the treatment of melanoma: implications for personalized medicine. Yale J Biol Med 88:4 (2015), 389–395.
12. 12 Petric, R.C., Pop, L.A., Jurj, A., et al. Next generation sequencing applications for breast cancer research. Clujul Med 88:3 (2015), 278–287.
13. 13 GENDEP Investigators, MARS Investigators, STAR*D Investigators, Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 170:2 (2013), 207–217.
14. 14 Winner, J., Allen, J.D., Altar, C.A., et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry, 3, 2013, e242.
15. 15 Hall-Flavin, D.K., Winner, J.G., Allen, J.D., et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry, 2, 2012, e172.
16. 16 Rush, A.J., Fava, M., Wisniewski, S.R., et al., STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 25:1 (2004), 119–142.
17. 17 Saragoussi, D., Chollet, J., Bineau, S., et al. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study. Int J Clin Pract 66:11 (2012), 1079–1087.
18. 18 Schultz, J., Joish, V., Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv 60:12 (2009), 1604–1611.
19. 19 Warden, D., Rush, A.J., Wisniewski, S.R., et al. What predicts attrition in second step medication treatments for depression? A STAR*D Report. Int J Neuropsychopharmacol 12:4 (2009), 459–473.
20. 20 Katz, A.J., Dusetzina, S.B., Farley, J.F., et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy 32:3 (2012), 234–243.
21. 21 Smits, K.M., Smits, L.J., Schouten, J.S., et al. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin Ther 29:4 (2007), 691–702.
22. 22 Serretti, A., Olgiati, P., Bajo, E., et al. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12:7 (2011), 501–515.
23. 23 Hornberger, J., Li, Q., Quinn, B., Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am J Manag Care 21:6 (2015), e357–e365.
24. 24 Lanktree, M.B., Zai, G., Vanderbeek, L.E., et al. Positive perception of pharmacogenetic testing for psychotropic medications. Hum Psychopharmacol 29:3 (2014), 287–291.
25. 25 Thomas, J.H., Rapid birth–death evolution specific to xenobiotic cytochrome P450 genes in vertebrates. PLoS Genet, 3(5), 2007, e67.
26. 26 Zanger, U.M., Schwab, M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:1 (2013), 103–141.
27. 27 Polimanti, R., Piacentini, S., Manfellotto, D., et al. Human genetic variation of CYP450 superfamily. Pharmacogenomics 13:16 (2012), 1951–1960.
28. 28 Chen, Q., Zhang, T., Wang, J.F., et al. Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 12:5 (2011), 436–444.
29. 29 Eap, C.B., Bender, S., Sirot, E.J., et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 24:2 (2004), 214–219.
30. 30 Narahari, A., El-Mallakh, R.S., Kolikonda, M.K., et al. How coffee and cigarettes can effect the response to psychopharmacotherapy. Current Psychiatry 14:10 (2015), 79–80.
31. 31 Xu, Q., Wu, X., Li, M., et al. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. Pharmacogenomics J, 2015 [Epub ahead of print].
32. 32 van de Bilt, M.T., Prado, C.M., Ojopi, E.P., et al. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. Schizophr Res 168:1–2 (2015), 587–588.
33. 33 Lanni, C., Racchi, M., Govoni, S., Do we need pharmacogenetics to personalize antidepressant therapy?. Cell Mol Life Sci 70:18 (2013), 3327–3340.
34. 34 Caspi, A., Sugden, K., Moffitt, T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003), 386–389.
35. 35 Luddington, N.A., Mandadapu, A., Husk, M., et al. Clinical implications of genetic variation in the serotonin transporter promoter region: a review. Prim Care Companion J Clin Psychiatry 11:3 (2009), 93–102.
36. 36 Karlović, D., Karlović, D., Serotonin transporter gene (5-HTTLPR) polymorphism and efficacy of selective serotonin reuptake inhibitors–do we have sufficient evidence for clinical practice. Acta Clin Croat 52:3 (2013), 353–362.
37. 37 Heils, A., Teufel, A., Petri, S., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 66:6 (1996), 2621–2624.
38. 38 Bradley, S.L., Dodelzon, K., Sandhu, H.K., et al. Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet 136:1 (2005), 58–61.
39. 39 Kaiser, R., Müller-Oerlinghausen, B., Filler, D., et al. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number tandem repeat of the serotonin transporter. Am J Med Genet 114:3 (2002), 323–328.
40. 40 Serretti, A., Olgiati, P., Liebman, M.N., et al. Clinical prediction of antidepressant response in mood disorders: linear multivariate vs. neural network models. Psychiatry Res 152:2–3 (2007), 223–231.
41. 41 Kato, M., Serretti, A., Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:5 (2010), 473–500.
42. 42 El-Mallakh, R.S., Gao, Y., Briscoe, B.T., et al. Tardive dysphoria: the role of long term antidepressant use in inducing chronic depression. Med Hypotheses 80:1 (2011), 57–59.
43. 43 Parsey, R.V., Hastings, R.S., Oquendo, M.A., et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 163:1 (2006), 48–51.
44. 44 Benedetti, F., Dallaspezia, S., Colombo, C., et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 25:8 (2010), 476–478.
45. 45 Hopkins, S.C., Reasner, D.S., Koblan, K.S., Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder. Psychiatry Res 208:3 (2013), 285–287.
46. 46 Atake, K., Yoshimura, R., Hori, H., et al. Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder. Neuropsychiatr Dis Treat 11 (2015), 967–974.
47. 47 Lin, J.Y., Jiang, M.Y., Kan, Z.M., et al. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord 168 (2014), 430–438.
48. 48 Kautzky, A., Baldinger, P., Souery, D., et al. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol 25:4 (2015), 441–453.
49. 49 Villafuerte, S.M., Vallabhaneni, K., Sliwerska, E., et al. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 19:6 (2009), 281–291.
50. 50 Nase, S., Köhler, S., Jennebach, J., et al. Role of serum brain derived neurotrophic factor and central N-Acetylaspartate for clinical response under antidepressive pharmacotherapy. Neurosignals 24:1 (2016), 1–14.
51. 51 Kocabas, N.A., Antonijevic, I., Faghel, C., et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26:1 (2011), 1–10.
52. 52 Su, N., Zhang, L., Fei, F., et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res 1415 (2011), 119–126.
53. 53 Musil, R., Zill, P., Seemüller, F., et al. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci 263:5 (2013), 405–412.
54. 54 Perlis, R.H., Moorjani, P., Fagerness, J., et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR*D Study. Neuropsychopharmacology 33 (2008), 2810–2819.
55. 55 Heurteaux, C., Lucas, G., Guy, N., et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9 (2006), 1134–1141.
56. 56 Huang, X., Yu, T., Li, X., et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics 14:14 (2013), 1723–1730.
57. 57 Breitenstein, B., Brückl, T.M., Ising, M., et al. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B:4 (2015), 274–283.
58. 58 Breitenstein, B., Scheuer, S., Brückl, T.M., et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res 73 (2015), 86–95.
59. 59 Chang, H.H., Chou, C.H., Yang, Y.K., et al. Association between ABCB1 polymorphisms and antidepressant treatment response in Taiwanese major depressive patients. Clin Psychopharmacol Neurosci 13:3 (2015), 250–255.
60. 60 Ray, A., Tennakoon, L., Keller, J., et al. ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J 15:4 (2015), 332–339.
61. 61 Breitenstein, B., Scheuer, S., Pfister, H., et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr 19:2 (2014), 165–175.
62. 62 Kirchheiner, J., Lorch, R., Lebedeva, E., et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9:7 (2008), 841–846.
63. 63 Stamm, T.J., Rampp, C., Wiethoff, K., et al. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J Psychopharmacol 30:1 (2016), 40–47.
64. 64 Hu, Q., Zhang, S.Y., Liu, F., et al. Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord 172C (2014), 103–109.
65. 65 Fabbri, C., Marsano, A., Albani, D., et al. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J 14:5 (2014), 463–472.
66. 66 Jiang, W., Xu, J., Lu, X.J., et al. Association between MTHFR C677T polymorphism and depression: a meta-analysis in the Chinese population. Psychol Health Med, 2015 [Epub ahead of print].
67. 67 Papakostas, G.I., Shelton, R.C., Zajecka, J.M., et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 169:12 (2012), 1267–1274.
68. 68 Papakostas, G.I., Shelton, R.C., Zajecka, J.M., et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 75:8 (2014), 855–863.
69. 69 Mischoulon, D., Lamon-Fava, S., Selhub, J., et al. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr 17:2 (2012), 76–86.
70. 70 Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (2014), 421–427.
71. 71 Lencz, T., Robinson, D.G., Xu, K., et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 163 (2006), 529–531.
72. 72 Zhang, J.P., Lencz, T., Malhotra, A.K., D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167 (2010), 763–772.
73. 73 Zhang, J.P., Robinson, D.G., Gallego, J.A., et al. Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis. Schizophr Bull 41:6 (2015), 1248–1255.
74. 74 Kang, S.G., Na, K.S., Lee, H.J., et al. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment. J Clin Psychopharmacol 35:2 (2015), 158–162.
75. 75 Lewis, A.G., Minchin, R.F., Lack of exonic sulfotransferase 4A1 mutations in controls and schizophrenia cases. Psychiatr Genet 19:1 (2009), 53–55.
76. 76 Meltzer, H.Y., Brennan, M.D., Woodward, N.D., et al. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr Res 106:2–3 (2008), 258–264.
77. 77 Ramsey, T.L., Meltzer, H.Y., Brock, G.N., et al. Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12:4 (2011), 471–480.
78. 78 Liu, Q., Ramsey, T.L., Meltzer, H.Y., et al. Sulfotransferase 4A1 haplotype 1 (SULT4A1-1) is associated with decreased hospitalization events in antipsychotic-treated patients with schizophrenia. Pharmacogenomics 12:4 (2011), 471–480.
79. 79 Wang, D., Li, Q., Favis, R., et al. SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response. Pharmacogenomics 15:12 (2014), 1557–1564.
80. 80 Huo, R., Wei, Z., Xiong, Y., et al. Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients. Neurosci Lett 584 (2015), 178–183.
81. 81 de Matos, L.P., Santana, C.V., Souza, R.P., Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response. Psychiatry Res 229:1–2 (2015), 586–588.
82. 82 Souza, R.P., Meltzer, H.Y., Lieberman, J.A., et al. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Hum Psychopharmacol 25:7–8 (2010), 582–585.
83. 83 Jenkins, A., Apud, J.A., Zhang, F., et al. Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology 39:9 (2014), 2170–2178.
84. 84 Terzić, T., Kastelic, M., Dolžan, V., et al. Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 11 (2015), 453–459.
85. 85 Fonseka, T.M., Tiwari, A.K., Gonçalves, V.F., et al. The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. World J Biol Psychiatry 16:1 (2015), 45–56.
86. 86 Bosia, M., Lorenzi, C., Pirovano, A., et al. COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics 16:1 (2015), 35–44.
87. 87 Grove, T., Taylor, S., Dalack, G., et al. Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. Schizophr Res 164:1–3 (2015), 115–121.
88. 88 Tiwari, A.K., Brandl, E.J., Zai, C.C., et al. Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. World J Biol Psychiatry 17:3 (2016), 221–229.
89. 89 Shi, S., Leites, C., He, D., et al. MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant. J Biol Chem 289:19 (2014), 13434–13444.
90. 90 Kao, A.C., Rojnic Kuzman, M., Tiwari, A.K., et al. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. J Psychiatr Res 54 (2014), 36–42.
91. 91 Roffeei, S.N., Reynolds, G.P., Zainal, N.Z., et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Hum Psychopharmacol 29:1 (2014), 38–45.
92. 92 Roffeei, S.N., Mohamed, Z., Reynolds, G.P., et al. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics 15:4 (2014), 477–485.
93. 93 Wang, F., Mi, W., Ma, W., et al. A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. Pharmacogenomics 16:17 (2015), 1943–1949.
94. 94 Lovallo, W.R., King, A.C., Farag, N.H., et al. Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma family health patterns project. Psychoneuroendocrinology 37:12 (2012), 1922–1928.
95. 95 Krystal, J.H., Cramer, J.A., Krol, W.F., et al., Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 (2001), 1734–1739.
96. 96 Gastpar, M., Bonnet, U., Böning, J., et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22:6 (2002), 592–598.
97. 97 Oslin, D.W., Berrettini, W., Kranzler, H.R., et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:8 (2003), 1546–1552.
98. 98 Ray, L.A., Bujarski, S., Chin, P.F., et al. Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37 (2012), 445–455.
99. 99 Gelernter, J., Gueorguieva, R., Kranzler, H.R., et al., VA Cooperative Study #425 Study Group. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31:4 (2007), 555–563.
100. 100 Karpyak, V.M., Biernacka, J.M., Geske, J.R., et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Translational Psychiatry, 4, 2014, e453.
101. 101 Spellicy, C.J., Kosten, T.R., Hamon, S.C., et al. The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Front Psychiatry, 3, 2012, 109.
102. 102 CDC Center for Public Health. Genomics, U.S. genome variation estimates: MTHFR allele and genotype frequencies. Available at: http://www.cdc.gov/genomics/population/file/print/genvar/mthfr.pdf. Accessed January 20, 2016.
103. 103 NIH NCBI Bookshelf. Chapter 3, pharmacology of medications used to treat opioid addiction. 2005. Available at: http://www.ncbi.nim.nih.gov. Accessed January 12, 2016.
104. 104 Bart, G., Kreek, M.J., Ott, J., et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30:2 (2005), 417–422.
105. 105 Reynolds, K.K., Ramey Hartung, B., Jortani, S.A., The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 28 (2008), 581–598.
106. 106 Crist, R.C., Clarke, T.M., Ang, A., et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 38 (2013), 2003–2010.
107. 107 Clarke, T.K., Crist, R.C., Ang, A., et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:3 (2014), 303–308.
108. 108 Verbelen, M., Lewis, C.M., How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?. Pharmacogenomics 16:9 (2015), 915–917.
109. 109 Cheung, Y.K., Cheng, S.H., Chan, E.J., et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54:7 (2013), 1307–1314.
110. 110 Hicks, J.K., Swen, J.J., Thorn, C.F., et al., Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:5 (2013), 402–408.
111. 111 Hicks, J.K., Bishop, J.R., Sangkuhl, K., et al., Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:2 (2015), 127–134.
112. 112 Swen, J.J., Nijenhuis, M., de Boer, A., et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 89:5 (2011), 662–673.
113. 113 de Leon, J., Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatr 26:6 (2014), 327–333.
114. 114 Mullins, N., Perroud, N., Uher, R., et al. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study. Am J Med Genet B Neuropsychiatr Genet 165B:5 (2014), 428–437.
115. 115 Lim, C.H., Zain, S.M., Reynolds, G.P., et al. Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 54 (2014), 157–162.